Edgewise Therapeutics appoints Michael Carruthers to be CFO

Edgewise Therapeutics appoints Michael Carruthers to be CFO

BOULDER -- Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael... Read More

Monday October 19, 2020 0 comments Tags: Boulder, Edgewise Therapeutics, Michael Carruthers, Kevin Koch

Edgewise Therapeutics closes $50M Series B financing round

Edgewise Therapeutics closes $50M Series B financing round

BOULDER -- Edgewise Therapeutics, a pre-clinical company developing small molecule therapies for musculoskeletal diseases, announced closing of a $50 million Series B financing round. The... Read More

Monday September 23, 2019 0 comments Tags: Boulder, Edgewise Therapeutics, Kevin Koch

Array forms strategic collaboration with Celgene Corp. to license clinical drug candidates

Array forms strategic collaboration with Celgene Corp. to license clinical drug candidates

BOULDER - Array BioPharma Inc . (Nasdaq: ARRY) announced a strategic collaboration with New Jersey-based Celgene Corporation for an Array-invented preclinical development program, targeting a... Read More

By: InnovatioNews Wednesday July 31, 2013 0 comments Tags: Array BioPharma, Boulder, Celgene Corp., Kevin Koch

Array BioPharma and Global Blood to collaborate on blood disease drug discovery

Array BioPharma and Global Blood to collaborate on blood disease drug discovery

BOULDER - Array BioPharma Inc . (Nasdaq: ARRY) and San Francisco-based Global Blood Therapeutics announced a multi-target drug discovery collaboration agreement to identify small molecule lead... Read More

By: Steve Wednesday March 6, 2013 0 comments Tags: Array BioPharma, Boulder, Kevin Koch